ALEMBIC PHARMACEUTICALS LTD. - 533573 - Proceedings Of The 10Th Annual General Meeting Held On 22Nd July, 2020
In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the 10th Annual General Meeting of the Company held on 22nd July, 2020. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), please find enclosed herewith schedule of the institutional investor meetings over video conference / voice over calls. We request you to kindly take the same on record and the same be treated as compliance under the applicable regulations of the SEBI LODR.
Earnings Call Transcript - Q1FY21 for Alembic Pharmaceuticals
Conference Call with Alembic Pharma Management and Analysts on Q1FY21 Performance and Outlook. Listen to the full earnings transcript. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Unaudited Financial Results For The Quarter Ended 30Th June, 2020
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter ended on 30th June, 2020. We enclose herewith the following: a) Consolidated Unaudited Financial Results for the quarter ended on 30th June, 2020. b) Standalone Unaudited Financial Results for the quarter ended on 30th June, 2020. c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results. d) Press Release. e) Investor Presentation. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 1:15 p.m. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Outcome Of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter ended on 30th June, 2020. We enclose herewith the following: a) Consolidated Unaudited Financial Results for the quarter ended on 30th June, 2020. b) Standalone Unaudited Financial Results for the quarter ended on 30th June, 2020. c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results. d) Press Release. e) Investor Presentation. The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 1:15 p.m. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 18th July, 2020 in Economic Times English Edition, Indian Express English Edition, Financial Express Gujarati Edition and on 20th July, 2020 in Economic Times Gujarati Edition. We request you to kindly take the same on record.
Alembic Pharma share price hits 52-week high on tentative US FDA approval for diabetes drug
Alembic now has a total of 126 ANDA approvals (111 final approvals and 15 tentative approvals) from USFDA. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Empagliflozin and Metformin Hydrochloride Tablets, 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 22nd July, 2020 as per the enclosed details. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2020
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2020 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Wednesday, 22nd July, 2020, to inter-alia consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2020. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st July, 2020, will re-open 48 hours after the declaration of the financial results on 22nd July, 2020. We request you to kindly take the same on record.